Fmoc-D-Tyr(tBu)-OHCAS# 118488-18-9 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 118488-18-9 | SDF | Download SDF |
| PubChem ID | 12968135 | Appearance | Powder |
| Formula | C28H29NO5 | M.Wt | 459.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid | ||
| SMILES | CC(C)(C)OC1=CC=C(C=C1)CC(C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24 | ||
| Standard InChIKey | JAUKCFULLJFBFN-RUZDIDTESA-N | ||
| Standard InChI | InChI=1S/C28H29NO5/c1-28(2,3)34-19-14-12-18(13-15-19)16-25(26(30)31)29-27(32)33-17-24-22-10-6-4-8-20(22)21-9-5-7-11-23(21)24/h4-15,24-25H,16-17H2,1-3H3,(H,29,32)(H,30,31)/t25-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Fmoc-D-Tyr(tBu)-OH Dilution Calculator
Fmoc-D-Tyr(tBu)-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1763 mL | 10.8814 mL | 21.7628 mL | 43.5256 mL | 54.407 mL |
| 5 mM | 0.4353 mL | 2.1763 mL | 4.3526 mL | 8.7051 mL | 10.8814 mL |
| 10 mM | 0.2176 mL | 1.0881 mL | 2.1763 mL | 4.3526 mL | 5.4407 mL |
| 50 mM | 0.0435 mL | 0.2176 mL | 0.4353 mL | 0.8705 mL | 1.0881 mL |
| 100 mM | 0.0218 mL | 0.1088 mL | 0.2176 mL | 0.4353 mL | 0.5441 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fmoc-D-Tyr(tBu)-OH
- Cyclo(L-Phe-trans-4-hydroxy-L-Pro)
Catalog No.:BCN3989
CAS No.:118477-06-8
- Arcyriaflavin A
Catalog No.:BCC7370
CAS No.:118458-54-1
- Licoricesaponin G2
Catalog No.:BCN7897
CAS No.:118441-84-2
- MK 886
Catalog No.:BCC7017
CAS No.:118414-82-7
- nTZDpa
Catalog No.:BCC7268
CAS No.:118414-59-8
- UNC 926 hydrochloride
Catalog No.:BCC2445
CAS No.:1184136-10-4
- AG-18
Catalog No.:BCC1051
CAS No.:118409-57-7
- Trimethylamine oxide
Catalog No.:BCN1819
CAS No.:1184-78-7
- Australine
Catalog No.:BCN2053
CAS No.:118396-02-4
- Licoricesaponin A3
Catalog No.:BCN7905
CAS No.:118325-22-7
- Tazarotene
Catalog No.:BCC2540
CAS No.:118292-40-3
- 6-O-Acetylscandoside
Catalog No.:BCN8320
CAS No.:118292-15-2
- 5,7-Dichlorokynurenic acid sodium salt
Catalog No.:BCC7758
CAS No.:1184986-70-6
- TRIS hydrochloride
Catalog No.:BCC7589
CAS No.:1185-53-1
- Myelin Basic Protein (87-99)
Catalog No.:BCC1028
CAS No.:118506-26-6
- LP 12 hydrochloride
Catalog No.:BCC7517
CAS No.:1185136-22-4
- DPPE fumarate
Catalog No.:BCC5669
CAS No.:1185241-83-1
- Sagittatoside A
Catalog No.:BCN2285
CAS No.:118525-35-2
- Sagittatoside B
Catalog No.:BCN2357
CAS No.:118525-36-3
- Sagittatoside C
Catalog No.:BCN3059
CAS No.:118525-37-4
- Icaritin
Catalog No.:BCN5352
CAS No.:118525-40-9
- Baohuoside V
Catalog No.:BCN2887
CAS No.:118544-18-6
- H-Orn(2-Cl-Z)-OH
Catalog No.:BCC3002
CAS No.:118553-99-4
- Boc-Orn(2-Cl-Z)-OH
Catalog No.:BCC3428
CAS No.:118554-00-0
Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.[Pubmed:20555127]
Hum Antibodies. 2010;19(1):15-25.
PR81 is a monoclonal antibody that binds with high affinity to MUC1, which is over expressed on breast and other tumors. The objective of this study was to compare the two labeling methods (direct and indirect radioiodination) for application of this antibody against MUC1 as a radioimmunotherapeutical agent.Monoclonal antibody (PR81) against the tandem repeat of the core protein (MUC1) was prepared, characterized, purified, and labeled with 131I using the direct (chloramin-T) and indirect (Fmoc-D-Tyr (tBu)-D-Tyr (tBu)-D-Lys (Boc)-OH (YYK) attached to N-hydroxysuccinimide as a linker between PR81 and 131I) methods. The immunoreactivity of 131I-PR81 and 131I-TP-PR81 complexes with MUC1 (the native protein), BSA-P20 (a 20 amino acid corresponding the tandem repeat of MUC1) and MCF7 cell line were performed by RIA. In vitro stability of 131I-PR81 and 131I-YYK-peptide-PR81 complexes in human serum was determined by thin layer chromatography (TLC). Cell toxicity and in vitro internalization studies were performed with the MCF7 cell line, and the tissue biodistribution of the 131I-PR81 and 131I- YYK-peptide -PR81 complexes was evaluated in normal BALB/c mice at 4, 24 and 48 hrs. The labeling efficiency was determined by measuring the percentage recovery of radioactivity in the final product relative to the initial activity in the shipment vial, was found to be 59.9% +/- 7.9% for direct and 50% +/- 3.2% for indirect methods. 131I-PR81 and 131I- YYK- peptide -PR81 complexes showed high immunoreactivity towards MUC1 protein, BSA-P20 and MCF7 cell line. In vitro stability of the labeled products in human serum which was measured by thin layer chromatography (TLC) was found to be more than 50% over 24 hr for 131I-PR81 and 70% for 131I- YYK-peptide -PR81 complexes. Cell toxicity and in vitro internalization studies showed that the 131I-PR81 and 131I- YYK-peptide -PR81 complexes inhibited 80% growth of the MCF7 cultured cell lines in vitro in a high concentration and up to 40% of the 131I-PR81 and 60% of the 131I- YYK-peptide -PR81 complexes internalized after 24 h. Biodistribution studies were performed in normal BALB/c mice at 4, 24 and 48 hrs post-injection. Thyroid and stomach levels from PR81 labeled with 131I- YYK-peptide were two- to three- fold less than those with directly labeled 131I-PR81, suggesting low recognition of its D-iodotyrosine residue by endogenous deiodinase. These results show that the indirect labeling was better than the indirect labeling and 131I- YYK-peptide -PR81 may be considered as a promising candidate for therapy of breast cancer.
